Urinary N-telopeptide levels in multiple myeloma patients, correlation with Tc-99m-sestaMIBIscintigraphy and other biochemical markers of disease activity

被引:9
作者
Alexandrakis, MG
Kyriakou, DS
Passam, FH
Malliaraki, N
Vlachonikolis, IG
Karkavitsas, N
机构
[1] Univ Hosp Heraklion, Dept Hematol, Iraklion, Crete, Greece
[2] Univ Hosp Thessalia, Dept Hematol, Thessalia, Greece
[3] Univ Hosp Crete, Dept Clin Biochem, Iraklion, Greece
[4] Med Sch Crete, Dept Biostat, Iraklion, Greece
[5] Univ Hosp Crete, Dept Nucl Med, Iraklion, Greece
关键词
N-telopeptide; Tc-99m sestaMIBI; TNF; multiple myelonta; bone resorption;
D O I
10.1002/hon.700
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Urinary cross-linked N-telopeptide of type I collagen (NTx) has been reported to be a sensitive and specific marker of bone resorption in multiple myeloma (MM). In this study, we measured the levels of NTx in 30 newly diagnosed MM patients and 25 controls. We examined its association with the overall score of skeletal involvement measured by Tc-99m-MIBI scintigraphy and other biochemical markers of bone disease (tumour necrosis factor a (TNF-a), serum calcium and creatinine). We further studied the correlation of NTx with the stage of disease (according to Durie-Salmon criteria) and bone marrow infiltration by plasma cells. High levels of NTx, bone marrow infiltration, TNF-alpha, calcium and creatinine were noted at advanced stages of disease (p < 0.05). NTx and TNF-a were found at significantly higher concentrations in patients with a high overall score (3 and 4) in Tc-99m-sestaMIBI in comparison to a low score (0, 1 and 2; p < 0.05). Positive correlations were found between NTx and TNF-a, as well as between bone infiltration and TNF-a or calcium. In conclusion, NTx is a useful marker for the monitoring of bone resorption in MM and correlates with imaging findings on Tc-99m-sestaMIBI and other biochemical markers of disease activity. Copyright (C) 2002 John Wiley Sons, Ltd.
引用
收藏
页码:17 / 24
页数:8
相关论文
共 27 条
[1]   Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma [J].
Abildgaard, N ;
Glerup, H ;
Rungby, J ;
Bendix-Hansen, K ;
Kassem, M ;
Brixen, K ;
Heickendorff, L ;
Nielsen, JL ;
Eriksen, EF .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2000, 64 (02) :121-129
[2]   Serum markers of bone metabolism in multiple myeloma: Prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP) [J].
Abildgaard, N ;
Bentzen, SM ;
Nielsen, JL ;
Heickendorff, L .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 96 (01) :103-110
[3]  
Alexandrakis MG, 2001, ANN HEMATOL, V80, P349
[4]  
Anderson KC, 1999, SEMIN HEMATOL, V36, P14
[5]   EXCESSIVE BONE-RESORPTION IN HUMAN PLASMACYTOMAS - DIRECT INDUCTION BY TUMOR-CELLS IN-VIVO [J].
BATAILLE, R ;
CHAPPARD, D ;
BASLE, M .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 90 (03) :721-724
[6]   STIMULATION OF BONE-RESORPTION AND INHIBITION OF BONE-FORMATION INVITRO BY HUMAN-TUMOR NECROSIS FACTORS [J].
BERTOLINI, DR ;
NEDWIN, GE ;
BRINGMAN, TS ;
SMITH, DD ;
MUNDY, GR .
NATURE, 1986, 319 (6053) :516-518
[7]  
Carlson K, 1999, EUR J HAEMATOL, V62, P300
[8]   THE ROLE OF INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA IN HUMAN MULTIPLE-MYELOMA [J].
CARTER, A ;
MERCHAV, S ;
SILVIANDRAXLER, I ;
TATARSKY, I .
BRITISH JOURNAL OF HAEMATOLOGY, 1990, 74 (04) :424-431
[9]  
Catalano L, 1999, HAEMATOLOGICA, V84, P119
[10]  
CHIU ML, 1990, J NUCL MED, V31, P1646